Notes to the Consolidated Financial Statements

1. General information

Biotalys NV (the “Company” or “Biotalys”) is a limited liability company governed by Belgian law. The address of its registered o ice is Buchtenstraat 11, 9051 Gent, Belgium. Since the successful IPO on 5 July 2021, the shares of Biotalys NV are listed on the regulated market of Euronext Brussels.

Biotalys and its subsidiary (together referred as the “Group”) is a development-stage, Agricultural Technology (AgTech) platform-based company focused on the discovery and development of novel biological products (protein-based biocontrols). The biocontrol products in the Group’s pipeline protect our food in a sustainable and safe manner and have the potential to address a broad range of food threats such as fungal diseases, insect pests and bacterial diseases with unique and novel modes of action. Biotalys filed with the Environmental Protection Agency (EPA) in the United States in December 2020, and with the European Food Safety Authority (EFSA) in March 2021, for the registration of Evoca™, its first protein based biofungicide. The Group does not yet have any commercialized products on the market.

The consolidated financial statements were authorized for issue by the Board of Directors on 21 March 2023.

Response to COVID-19

Since the outbreak of the COVID-19 pandemic in March 2020 in Europe, Biotalys put in place all the internal measures to protect its employees according to the rules and regulations established by the Belgian and European authorities. Home working was strongly encouraged and IT infrastructure and security have been upgraded to allow e icient remote working. Shi s have been established for essential laboratory personnel to maintain essential activities while optimizing the number of employees working on site.

The impact of COVID-19 on Biotalys’ financial situation has been limited in 2022. While a continued spread of COVID-19 or similar pandemics and the measures taken by the governments of countries a ected could adversely impact Biotalys’ financial condition and may result in longer development timelines and costs, Biotalys expects to be able to continue its activities under the most restrictive lock-down conditions established so far.